(A) EFS and OS with Total Therapy from initiation of VAD. Median durations have been reached at 3.6 and 5.7 years, respectively. (B) Time to disease progression or relapse (see text) since initiation of therapy, with toxic or incidental deaths not related to disease progression/relapse being censored. TRM was 7% by 2 years.